FMED Fact Sheet: Fidelity Disruptive Medicine ETF
Share
$32.74
close, Nov 20, 2026
Over the year to Nov 19, 2026, FMED returned +19.6% in total and charged 0.50% a year.
- 1-year total return
- +20.2%
- to Nov 20, 2026
- Expense ratio
- 0.50%
- a year
- Net assets
- $53m
- on Oct 31, 2026
- Net flow, 12 months to Aug 31, 2026
- −$14.6m
- monthly N-PORT basis to Aug 31, 2026
Growth of $10,000, 1 year
FMED $11,957 +19.6% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.
Returns
WindowTotal return
1 month+2.3%
3 months+0.6%
Year to date+21.0%
1 year+20.2%
3 years+53.8%
Total return, distributions reinvested, each window to Nov 20, 2026.
Ten largest positions
HoldingWeight
10X GENOMICS INC5.19%
THERMO FISHER SCIENTIFIC INC3.83%
DANAHER CORP3.73%
NATERA INC3.30%
ARGENX SE3.20%
LIFESTANCE HEALTH GROUP INC3.00%
REVOLUTION MEDICINES INC2.87%
ILLUMINA INC2.82%
MODERNA INC2.72%
HEARTFLOW INC2.59%
FMED top ten by weight, 33.2% of the fund, of its 72 equity positions, from the holdings filed for Aug 31, 2026.
Facts
Holds 72 stocks in broad innovation and megatrends, 22% of its weight in S&P 500 companies · First traded Jun 12, 2023 · Benchmark Its own holdings, as of Aug 31, 2026; its prospectus names no index it tracks